Home/ Stocks/ RCUS

Arcus Biosciences, Inc.

RCUS XNYS

$28.62 +0.29 (+1.02%) ▲ 15-min delayed

Open

$28.98

High

$29.11

Low

$28.01

Volume

1.06M

Market Cap

$3.61B

About Arcus Biosciences, Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 601 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$41.00M	$-91,000,000	$-0.72
Q1 2026	$17.00M	$-128,000,000	$-1.02
FY 2025	$247.00M	$-353,000,000	$-3.29
Q3 2025	$26.00M	$-135,000,000	$-1.27

Related Market News

No specific coverage for RCUS yet. Check out our latest market news or earnings calendar.

Get RCUS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Arcus Biosciences, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.